[go: up one dir, main page]

AR084705A1 - Formas cristalinas de n-[2-[[(2,3-difluorofenil)metil]tio]-6-{[(1r,2s)-2,3-dihidroxi-1-metilpropil]oxi}-4-pirimidinil]-1-azetidinsulfonamida - Google Patents

Formas cristalinas de n-[2-[[(2,3-difluorofenil)metil]tio]-6-{[(1r,2s)-2,3-dihidroxi-1-metilpropil]oxi}-4-pirimidinil]-1-azetidinsulfonamida

Info

Publication number
AR084705A1
AR084705A1 ARP110102510A ARP110102510A AR084705A1 AR 084705 A1 AR084705 A1 AR 084705A1 AR P110102510 A ARP110102510 A AR P110102510A AR P110102510 A ARP110102510 A AR P110102510A AR 084705 A1 AR084705 A1 AR 084705A1
Authority
AR
Argentina
Prior art keywords
azetidinsulfonamide
difluorophenyl
methylpropyl
pyrimidinyl
methyl
Prior art date
Application number
ARP110102510A
Other languages
English (en)
Inventor
Britt Anne Ingela Gullberg
Thomas Peter Larsson
Jeffrey Paul Stonehouse
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR084705A1 publication Critical patent/AR084705A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proporcionan formas cristalinas de anhidrato de N-[2-[[(2,3-difluorofenil)metil]tio]-6-{[(1R,2S)-2,3-dihidroxi-1-metilpropil]oxi}-4-pirimidinil]-1-azetidinsulfonamida. Tales compuestos/formas pueden ser útiles en el tratamiento de una enfermedad/afección en la que es beneficioso modular la actividad de los receptores de quimiocinas.
ARP110102510A 2010-07-13 2011-07-13 Formas cristalinas de n-[2-[[(2,3-difluorofenil)metil]tio]-6-{[(1r,2s)-2,3-dihidroxi-1-metilpropil]oxi}-4-pirimidinil]-1-azetidinsulfonamida AR084705A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36372610P 2010-07-13 2010-07-13

Publications (1)

Publication Number Publication Date
AR084705A1 true AR084705A1 (es) 2013-06-05

Family

ID=44358090

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110102510A AR084705A1 (es) 2010-07-13 2011-07-13 Formas cristalinas de n-[2-[[(2,3-difluorofenil)metil]tio]-6-{[(1r,2s)-2,3-dihidroxi-1-metilpropil]oxi}-4-pirimidinil]-1-azetidinsulfonamida

Country Status (16)

Country Link
US (2) US8748603B2 (es)
EP (1) EP2593448A1 (es)
JP (1) JP2013531027A (es)
KR (1) KR20130103483A (es)
CN (1) CN103097377A (es)
AR (1) AR084705A1 (es)
AU (1) AU2011278115B2 (es)
BR (1) BR112013000788A2 (es)
CA (1) CA2804162A1 (es)
MX (1) MX2013000289A (es)
MY (1) MY167869A (es)
RU (1) RU2548044C2 (es)
SG (1) SG186859A1 (es)
TW (1) TWI496773B (es)
UY (1) UY33506A (es)
WO (1) WO2012007748A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6262286A (ja) * 1985-09-13 1987-03-18 株式会社東芝 沸騰水型原子炉炉心
EP2593448A1 (en) * 2010-07-13 2013-05-22 AstraZeneca AB New cristalline forms of n-[2-[[(2,3-difluoropheny)methyl)thio]-6-{[(1r,2s)-2,3- dihydroxy-1-methylpropyl]oxy}-4-pyrimidinyl]-1-azetidinesulfonamide
MX353334B (es) * 2011-07-12 2018-01-09 Astrazeneca Ab N-(6-((2r,3s)-3,4-dihidroxibutan-2-iloxi)-2-(4-fluorobenciltio)pi rimidin-4-il)-3-metilacetidina-1-sulfonamida como modulador del receptor de quimiocina.
EP3141235A1 (en) * 2012-12-06 2017-03-15 IP Gesellschaft für Management mbH N-(6-((2r,3s)-3,4-dihydroxybutan-2-yloxy)-2-(4-fluorobenzylthio)pyrimidin-4-yl)-3-methylazetidine-l -sulfonamide
CN103113333B (zh) * 2012-12-20 2015-07-08 浙江普洛康裕制药有限公司 一种维生素c乙基醚的合成方法
EP3220951A1 (en) * 2014-11-17 2017-09-27 MedImmune Limited Therapeutic combinations and methods for treating neoplasia
MX386771B (es) 2016-03-11 2025-03-19 Ardea Biosciences Inc Inhibidores de cxcr-2 para tratamiento de trastornos de artropatía por cristales.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0217431D0 (en) 2002-07-27 2002-09-04 Astrazeneca Ab Novel compounds
RS53145B (sr) * 2004-08-28 2014-06-30 Astrazeneca Ab. Pirimidin sulfonamidni derivati kao modulatori hemokinskih receptora
EP2315754A1 (en) 2008-07-16 2011-05-04 AstraZeneca AB Pyrimidyl sulfonaminde derivative and its use for the treatment of chemokine mediated diseases
JP2011529027A (ja) 2008-07-25 2011-12-01 ビーエーエスエフ ソシエタス・ヨーロピア ３−アミノメチル−１−シクロヘキシルアミン、及びその製造方法
EP2593448A1 (en) * 2010-07-13 2013-05-22 AstraZeneca AB New cristalline forms of n-[2-[[(2,3-difluoropheny)methyl)thio]-6-{[(1r,2s)-2,3- dihydroxy-1-methylpropyl]oxy}-4-pyrimidinyl]-1-azetidinesulfonamide
MX353334B (es) 2011-07-12 2018-01-09 Astrazeneca Ab N-(6-((2r,3s)-3,4-dihidroxibutan-2-iloxi)-2-(4-fluorobenciltio)pi rimidin-4-il)-3-metilacetidina-1-sulfonamida como modulador del receptor de quimiocina.

Also Published As

Publication number Publication date
CA2804162A1 (en) 2012-01-19
AU2011278115B2 (en) 2014-11-06
US20140235606A1 (en) 2014-08-21
CN103097377A (zh) 2013-05-08
RU2548044C2 (ru) 2015-04-10
SG186859A1 (en) 2013-02-28
TWI496773B (zh) 2015-08-21
UY33506A (es) 2012-02-29
MX2013000289A (es) 2013-03-08
EP2593448A1 (en) 2013-05-22
TW201209041A (en) 2012-03-01
BR112013000788A2 (pt) 2017-09-26
WO2012007748A1 (en) 2012-01-19
RU2013103754A (ru) 2014-08-20
JP2013531027A (ja) 2013-08-01
MY167869A (en) 2018-09-26
US8748603B2 (en) 2014-06-10
AU2011278115A1 (en) 2013-01-24
KR20130103483A (ko) 2013-09-23
US20120015927A1 (en) 2012-01-19

Similar Documents

Publication Publication Date Title
AR084705A1 (es) Formas cristalinas de n-[2-[[(2,3-difluorofenil)metil]tio]-6-{[(1r,2s)-2,3-dihidroxi-1-metilpropil]oxi}-4-pirimidinil]-1-azetidinsulfonamida
PE20110136A1 (es) Compuestos organicos
UA112061C2 (uk) Активуючі ampk гетероциклічні сполуки і способи їх використання
CU20130082A7 (es) 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr
EA201270597A1 (ru) Соединения, модулирующие андрогеновые рецепторы
UA116809C2 (uk) Застосування агрохімічних сумішей для збільшення життєздатності рослини
CL2011002706A1 (es) Compuestos derivados de 4-(1,3-oxazol-2-il)-1h-indazol; composicion farmaceutica que los comprende; y sus usos en el tratamiento de enfermedades tales como epoc, autoinmunes, asma, entre otras.
PE20120620A1 (es) Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasas
PE20130009A1 (es) Inhibidores de la replicacion del virus de la inmunodeficiencia humana
EA201500574A1 (ru) Новые инданилоксидигидробензофуранилуксусные кислоты
RU2015105825A (ru) Композиция для борьбы с болезнями растений и ее применение
CL2013001558A1 (es) El uso de compuestos moduladores o agonistas de los receptores de s1p para disminuir la frecuencia cardiaca en aproximadamente 2 latidos/minuto; metodo para aminorar, prevenir o limitar un efecto cronotropico negativo; un kit farmaceutico.
EA201490616A1 (ru) Использование ацилсульфонамидов для улучшения урожайности растений
BR112012030408A2 (pt) método de melhoramento de culturas
AR124688A2 (es) Una pirimidina sulfonamida o un tautómero del mismo, o una sal farmacéuticamente aceptable del mismo
PE20140934A1 (es) Derivados de pirazol
UY32409A (es) Compuesto de anillo fusionado y su uso
EA201400067A1 (ru) Новая терапевтическая композиция, содержащая апоморфин в качестве активного ингредиента
UY29184A1 (es) Derivados de sulfonilbencimidazol
PE20150284A1 (es) Derivado de indanosulfamida novedoso
AR077227A1 (es) Compuesto de acido aril/ heteroaril- sustituido carboxilico, su uso para fabricar un medicamento util el tratamiento de afecciones o trastornos mediados por receptores s1p1, tales como esclerosis multiple y composicion farmaceutica que lo comprende
AR093042A1 (es) Derivados de etinilo
CR11360A (es) Benzotiazoles como moduladores del receptor de grelina
PE20090624A1 (es) Diaminopirimidinas
UY31824A (es) Nuevos compuestos

Legal Events

Date Code Title Description
FB Suspension of granting procedure